Regorafenib for previously treated metastatic colorectal cancer

2.1 Regorafenib (Stivarga, Bayer) is indicated for 'the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy'.

2.2 The dosage schedule is available in the summary of product characteristics for regorafenib.

2.3 The list price of regorafenib 40 mg is £3,744 per 84 tablets (excluding VAT; BNF online accessed November 2022).

2.4 The company has a commercial arrangement. This makes regorafenib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.